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vided a single, overall score for each product. Cigarettes 
(overall weighted score of 100) emerged as the most harmful 
product, with small cigars in second place (overall weighted 
score of 64). After a substantial gap to the third-place prod-
uct, pipes (scoring 21), all remaining products scored 15 
points or less.  Interpretation: Cigarettes are the nicotine 
product causing by far the most harm to users and others in 
the world today. Attempts to switch to non-combusted 
sources of nicotine should be encouraged as the harms from 
these products are much lower.  © 2014 S. Karger AG, Basel 
 Introduction 
 The recreational use of tobacco remains one of  the 
principal causes of chronic ill health and early death world-
wide. The tobacco epidemic was largely reflected in more 
affluent Western countries but, increasingly, the illnesses 
associated with tobacco use have spread to the developing 
world  [1] . Cigarettes are considered to be the most harm-
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 Abstract 
 Background: An international expert panel convened by the 
Independent Scientific Committee on Drugs developed a 
multi-criteria decision analysis model of the relative impor-
tance of different types of harm related to the use of nico-
tine-containing products.  Method: The group defined 12 
products and 14 harm criteria. Seven criteria represented 
harms to the user, and the other seven indicated harms to 
others. The group scored all the products on each criterion 
for their average harm worldwide using a scale with 100 de-
fined as the most harmful product on a given criterion, and 
a score of zero defined as no harm. The group also assessed 
relative weights for all the criteria to indicate their relative 
importance.  Findings: Weighted averages of the scores pro-
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ful tobacco product although other forms of tobacco used 
recreationally may also result in harm to the user  [2] .
 It is now widely accepted that the compulsive use of 
 tobacco reflects the development of dependence upon the 
nicotine present in tobacco and many of the pharmaco-
logical interventions that are employed to aid smoking ces-
sation target this dependence  [3, 4] . However, in experi-
mental animals, nicotine does not have the potent addic-
tive properties that are required to explain the powerful 
addiction to tobacco experienced by many habitual smok-
ers  [5, 6] . Thus, it has been proposed that other pharmaco-
logically active substances present in tobacco smoke and 
the conditioned sensory stimulation associated with inhal-
ing tobacco smoke have a significant role in the develop-
ment of dependence upon tobacco  [7–10] . Pharmacologi-
cal nicotine replacement products (NRT) were introduced 
as aids to smoking cessation in the late 1970s and continue 
to be used extensively in the treatment of tobacco depen-
dence. Experience with these preparations suggests that 
their use is not associated with an increased risk of chron-
ic obstructive pulmonary disease, lung cancer or cardio-
vascular disease  [3, 11] although there are reports that nic-
otine may be metabolized to compounds that are poten-
tially carcinogenic  [12, 13] .  Furthermore, studies with 
experimental animals suggest that the ingestion of nico-
tine during pregnancy can have adverse effects on the brain 
development of the fetus and the vulnerability of the prog-
eny to nicotine dependence  [14, 15] . Relatively little direct 
information is available for the effects of maternal nicotine 
on human development and behaviour. However, smoke-
less tobacco has been found to have a negative effect  [16] 
and Bruin et al.  [17] have argued that the possibility of 
 adverse effects for both the mother and fetus of NRT use 
during pregnancy should not be disregarded. Thus, indi-
vidual researchers have expressed differing opinions on 
the safety of pharmacological nicotine. Nevertheless, some 
40 years’ experience with NRT preparations suggest that 
they are safe and are not associated with significant adverse 
medical consequences  [4] . This conclusion is consistent 
with the compelling evidence that many of the adverse 
health effects of inhaling tobacco smoke are caused by oth-
er components of the smoke such as nitrosamines, carbon 
monoxide and nitric oxide  [18, 19] . Thus, despite some 
differences in opinion, it seems that tobacco use lends itself 
rather better than many other forms of addiction to a harm 
reduction approach using pharmacological interventions 
including therapeutic nicotine preparations.
 Most attention with regard to the harmful effects of 
tobacco use has focused on cigarettes and the evidence that 
they cause chronic illness and early death is compelling. 
However, other forms of tobacco use also need to be con-
sidered. There is good evidence, for example, that  Swedish 
snus, a form of refined oral tobacco which is low in nitro-
samines, is at worst only weakly associated with an in-
creased risk of cancer or cardiovascular disease  [20] . By 
contrast, other smokeless unrefined oral tobacco prod-
ucts seem to be associated with significantly more harm 
to the user  [21] . For example, the chronic use of gutkha, 
a form of smokeless tobacco popular with members of the 
Asian community, is associated with the development of 
disorders of the oral mucosa and oral cancer  [22] . Water 
pipes, widely used in the Middle East, are finding increas-
ing favour in Western society. The potential toxic effects 
of water pipe smoke have not yet been fully evaluated al-
though some concerns have been expressed about the po-
tential adverse consequences for health of using this form 
of tobacco  [23, 24] . Our understanding of the potential 
hazards associated with using electronic nicotine delivery 
systems (ENDS, e.g. E-cigarettes) is at a very early stage. 
These delivery systems are seen as an acceptable form of 
recreational nicotine use with a minimal potential for sec-
ond-hand environmental contamination. Nevertheless, 
there is concern that these devices should not be intro-
duced in an unregulated way until potential associated 
harms are adequately evaluated  [25] .
 There remains a need for policy makers to become bet-
ter informed of the relative harms of nicotine delivery sys-
tems in order to build a regulatory framework that mini-
mizes harm. The aim of the current study was to convene 
a group of experts with expertise in the field of nicotine and 
tobacco research from different disciplines (animal and be-
havioural pharmacology, toxicology, medicine, psychiatry, 
policy and law) that could discuss and agree on the harm-
fulness of nicotine-containing products using a multi-cri-
teria decision analysis (MCDA) model and, thus, provide a 
sound framework within which policy makers might work.
 Methods 
 Study Design 
 The Independent Scientific Committee on Drugs selected ex-
perts from several different countries to ensure a diversity of ex-
pertise and perspective, as evident from the author list. The MCDA 
process  [26] was conducted during a 2-day facilitated workshop 
held in London in July 2013. The MCDA model for the harm of 
psychoactive drugs developed by the Independent Scientific Com-
mittee on Drugs in 2010  [27] provided a starting point for this 
nicotine harm study, as it covered all the potential parameters of 
harm that might potentially be caused by any drug.
 The MCDA process is a way to compare variables of harm in 
widely different areas where traditional metrics are not available. 
It works through a series of eight stages: (1) establishing context; 
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(2) agreeing on the products to be evaluated and producing defini-
tions of these; (3) agreeing on the criteria on which the products 
were to be compared; (4) scoring the products on each criterion; 
(5) weighting the criteria; (6) calculating weighted scores to give 
an overall index of the harm of each product; (7) examining results 
and resolving any inconsistencies, and (8) exploring the sensitivity 
of the indices to different assessments of scores and weights.
 The Context 
 The group recognized that there are regional and national dif-
ferences in actual and perceived harm of nicotine products, so par-
ticipants agreed to take a worldwide perspective and consider aver-
age harm.
 The Nicotine Products 
 After considering many nicotine products and the criteria for 
comparing the products, the group discussed steps 2 and 3 above in 
a reciprocal and iterative way so that the final set of products was 
substantially different from one another in important ways.  Table 1 
gives the final agreement about the products and their definitions.
 The Criteria of Harms 
 The group reviewed the 16 criteria that had first been agreed by 
the UK Advisory Council on the Misuse of Drugs  [28] and used by 
the Independent Scientific Committee on Drugs in their 2010 deci-
sion conference on 20 psychoactive drugs  [27] . All but two criteria 
were retained but where necessary were redefined to be relevant to 
nicotine products. The two that were dropped were drug-specific 
and drug-related mental impairment as it was thought that there 
was little evidence for these with any of the nicotine products.
 The criteria against which the products were evaluated are shown 
at the extreme right of the harm tree in  figure 1 . The main objective 
was to determine an ordering of the products at the ‘Product harms’ 
node. The next level to the right provides separate harm groupings 
of the criteria: ‘To users’ (harm to those who are using the product) 
and ‘To others’ (harm as a consequence of the use of the product to 
others both directly and indirectly). Assessments of the harms for all 
products were made against the criteria given at the extreme right of 
the value tree. The final definitions are shown in  table 2 .
 Scoring the Products 
 The group scored all products on all criteria. The scoring sys-
tem used points out of 100, with 100 assigned to the most harmful 
product on a given criterion and zero representing ‘no harm’.
 In scaling the products, care is required to ensure that each suc-
cessive point on the scale represents equal increments of harm. 
Thus, if a product is scored at 50, then it should be half as harmful 
as the product scored 100. Because zero represents no harm, this 
scale can be considered a ratio scale, which makes possible ratio 
comparisons of the weighted scales.
 Weighting 
 Some criteria are more important expressions of harm than oth-
ers, so weighting of the criteria is required. ‘Swing weighting’ pro-
vides weights that are meaningful in MCDA. As an analogy, both 
Fahrenheit and Celsius scales contain 0–100 portions, but the swing 
in temperature from 0 to 100 on the Fahrenheit scale is, of course, 
a smaller swing in temperature than 0–100 on a Celsius scale; it 
takes 5 Celsius units to equal 9 Fahrenheit units. The purpose of 
weighting is to ensure that the units of harm on the different harm 
scales are equivalent, thus enabling weighted scores to be compared 
and combined across the criteria. Weights are scale factors.
 To assess scale factors two steps in thinking must be separated. 
First, it is necessary to think about the difference in harm between 
the most and least harmful products on that criterion. The next step 
is to think about how much that difference in harm matters in a giv-
en context. ‘How big is the difference in harm and how much do you 
care about that difference?’ This is the question that was posed in 
comparing the 0-to-100 swing in harm on one scale with the 0-to-100 
swing on another scale, assuming the harm is a worldwide average.
 Swing weights for the User criterion were assessed first; the 
largest swing, on Product-specific morbidity, the difference be-
tween cigarettes and nasal sprays was assigned a weight of 100. 
Next, weights were judged for the criteria at the Other node: the 
largest swing, the difference between cigarettes and small cigars for 
Economic cost, was set at 100. Finally, those two 100’s were com-
pared by judging their swing weights. The swing for Product-re-
 Table 1.  The 12 products considered during the decision confer-
ence and their definitions
Cigarettes manufactured and hand-rolled cigarettes in which 
the tobacco is wrapped in paper
Cigars smoked cigars: roll of tobacco wrapped in tobacco 
leaf
Little and
small cigars
used like a cigarette wrapped in tobacco leaf, 
sometimes with a filter (a product that has 
emerged in response to the US tobacco taxation 
system and would, in most jurisdictions be 
 considered cigarettes)
Pipes a tube with a small bowl at one end for smoking 
tobacco
Water pipe a pipe where tobacco smoke is bubbled through 
water
Smokeless
refined
non-snus (and other) smokeless refined tobacco 
products used orally, including moist chewing 
tobacco and snuff (common in USA)
Smokeless
unrefined
non-snus (and other) smokeless unrefined 
 tobacco products used orally, including chewing 
tobacco and dry snuff (products common in SE 
Asia)
Snus a low nitrosamine and non-fermented smokeless 
tobacco product (popular in Scandinavia and now 
in USA)
ENDS electronic nicotine delivery system products, 
e.g. e-cigs (electronic cigarettes either cigarette-
like or personal vaporizers)
Oral 
products
oral nicotine delivery products (including NRT 
products)
Patch dermal nicotine delivery products
Nasal sprays nasal nicotine delivery products
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Community
Economic cost
International damage
Family adversities
Environmental damage
Crime
Injury
Loss of relationship
Loss of tangibles
Dependence
Product-related morbidity
Product-specific morbidity
Product-related mortality
Product-specific mortality
To users
To others
Product harms
 Fig. 1. Evaluation criteria organized by 
harms to users and harms to others. 
 Table 2.  Definitions of the evaluation criteria for the nicotine products
Name Description
Product-specific
mortality
deaths directly attributed to product misuse or abuse as in the case of accidental and deliberate poisoning
Product-related 
mortality
deaths indirectly attributed to the product, e.g. death due to cancer, respiratory illness, cardiovascular disease and fire
Product-specific
morbidity
damage (morbidity, chronic ill health) to physical health directly attributed to product misuse or abuse, e.g.  ulcers, 
lung disease, heart disease
Product-related
morbidity
damage to physical health indirectly attributed to product misuse or abuse, e.g. burns, allergies
Dependence extent to which the product creates a propensity or urge to continue use despite adverse consequences and causes 
 withdrawal symptoms on cessation
Loss of tangibles extent of loss of tangible things (e.g. income, housing, job)
Loss of relationships extent of loss of relationships with family and friends
Injury the extent to which the product increases chances of injuries to others both directly and indirectly, e.g. traffic accident, 
fetal harm, second-hand smoke, accidental poisoning, burns
Crime the extent to which the use of the product increases criminal behaviour (e.g. smuggling) directly or indirectly (at the 
population level, not the individual)
Environmental
damage
the extent to which the use and production of this product causes environmental damage locally, e.g. fires, competition 
for arable land, cigarette stub pollution
Family adversities the extent to which the use of the product causes family adversities, e.g. economic well-being, future prospects of children
International
damage
the extent to which the use of the product contributes to damage at an international level, e.g. deforestation, 
 contraband as criminal activity, counterfeiting
Economic cost the extent to which the use of the product results in effects that create direct costs to countries (e.g. health-care costs, 
customs) and indirect costs (e.g. loss of productivity, absenteeism)
Community the extent to which the use of the product creates decline in social cohesion and decline in the reputation of the community
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lated morbidity was weighted as the larger harm that matters, so 
its weight of 100 was retained. The swing for Economic cost was 
assessed as 70% of that, so the original weights for all the Econom-
ic criteria were multiplied by 0.70.
 As scores and weights were agreed, they were input to the Hiview 
computer program 1 , which normalized the weights so they summed 
to 100, calculated the weighted scores and displayed the results.
 Results 
 Figure 2 shows the overall weighted scores of the nico-
tine products as stacked bar graphs. Cigarettes and small 
cigars are each several times more harmful than any of the 
other products. Similarly coloured sections of the bar 
graphs show a given criterion’s weighted harm value as it 
contributes to the overall weighted scores of the nicotine 
products. Thus, Product-related mortality and Product-
specific morbidity are the main harms for cigarettes and 
small cigars, while Economic cost is also a substantial 
contributor to the overall harm for cigarettes.
 The stacked bar graphs can also be shown for their 
separate contributions of harm ‘To users’ and harm ‘To 
others’.  Figure 3 gives the harm to users as the blue sec-
tion, and harm to others as red. Harm to others makes a 
substantial contribution only to cigarettes, and virtually 
none to the other 11 products. 
 Why are cigarettes considered the most harmful?  Figure 
4 shows the contribution that each criterion makes to ciga-
rettes’ total weighted score. Each row in the display gives the 
part-score for that criterion (Wtd Diff), and it is the sum of 
those part scores that gives the overall score of 99.6. These 
part-scores determine the relative heights of each of the 
 coloured bands for the cigarettes’ bar graph in  figure 4 . 
Note that cigarettes were assigned harm scores of 100 on 12 
of the 14 criteria, but that just five of those 14 collectively 
contribute a score of 92.7, nearly as much as the total of 99.6.
 Both cigarettes and small cigars score 100 on three of 
the most important criteria: Product-specific morbidi-
 Fig. 2. Overall weighted scores for each of the products. Cigarettes, 
with an overall harm score of 99.6, are judged to be most harmful, 
and followed by small cigars at 67. The heights of the coloured por-
tions indicate the part scores on each of the criteria. Product-relat-
ed mortality, the upper dark red sections, are substantial contribu-
tors to those two products, and they also contribute moderately to 
cigars, pipes, water pipes, and smokeless unrefined. The numbers 
in the legend show the normalized weights on the criteria. Higher 
weights mean larger differences that matter between most and 
least harmful products on each criterion. 
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ty, Product-related mortality and Dependence. Those 
three are harms to the users, criteria which do not take 
account of the extent of usage worldwide. However, cig-
arettes also score 100 on Economic cost and Injury, 
which are harms to others that do take account of glob-
al usage. It is those two criteria that account for the dif-
ference in the total scores of cigarettes compared to 
small cigars.
 Discussion 
 Perhaps not surprisingly, given their massively great-
er use as compared with other products, cigarettes were 
ranked the most harmful, followed by small cigars as two 
thirds as harmful. It is only the relative lack of harm to 
others that positioned small cigars at two thirds the harm 
of cigarettes. For both these products the bulk of the 
 Fig. 3. The products ordered by their over-
all harm scores, with the stacked bar graphs 
showing the contribution to the overall 
score of harms to users and harm to others. 
The numbers in the legend show the sums 
of the normalized weights at each node. 
 Fig. 4. The relative harms of cigarettes. The 
cumulative weight (Cum Wt) column 
shows the normalized weight for each cri-
terion. The harm score for cigarettes, 
shown in the Diff column, on each criteri-
on is multiplied by the cumulative weight 
of the corresponding criterion to give a 
weighted score (i.e., a part-score), shown in 
the Wtd Diff column. The lengths of the 
green bars are proportional to the weighted 
scores, so the longer the green bars, the 
more that harm matters for its effects from 
cigarettes. 
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harm came from morbidity and mortality areas such as 
cancer, respiratory and cardiovascular disease, followed 
by Economic cost, Injury and Dependence. There was a 
big drop in harm from small cigars (67% of maximum 
relative harm, MRH) to pipes 22%. Within the tobacco 
products there was a gradual reduction in harm from 
water pipe, smokeless unrefined, smokeless refined to 
snus that has 5% of MRH. Among the purer non-tobacco 
vehicle products ENDS were rated to have only 4% of 
MRH and for the even purer NRTs the MRH was only 
rated at about 2%. Thus there is wide variability in harm 
among the combustible tobacco-based products, from 
cigarettes (100%) to water pipe (14%) and even more 
within the tobacco-based category, from cigarettes 
(100%) to snus (5%). Not surprisingly the purest prod-
ucts, NRTs, with few other ingredients than nicotine 
were the least harmful and pose little risk for intrinsic 
harm when used for the treatment of tobacco depen-
dence. Indeed their use would bring significant benefits 
not just to users but also to non-smokers and society as 
a whole.
 Clearly this exercise speaks to a continuum of harm 
from nicotine-containing products with cigarettes at 
one end and NRT products at the other end. The differ-
ences between the products are substantial and if policy 
actions could help to switch use away from cigarettes 
and other smoked products to purer nicotine products, 
such as NRT products, massive public health gains 
would occur.
 There is also some evidence that the cigarettes are the 
most dependence-forming product and products with 
less harm also may be less dependence-forming  [9] . An 
analogue can be found with alcohol where most coun-
tries have policies that steer consumption as much as 
possible to alcohol-containing beverages with a low alco-
hol content.
 A limitation of this study is the lack of hard evidence 
for the harms of most products on most of the criteria. 
That is why we adopted the decision conferencing pro-
cess: the group of experts worked face-to-face in a peer-
review setting with impartial facilitation, sharing relevant 
data, knowledge and experience to ensure that all per-
spectives were heard. It is the combination of impartial 
facilitation, modelling (in this case, MCDA), and infor-
mation technology (projecting the MCDA model for the 
group to observe as it was constructed and explored) that 
enables a group to outperform its members, thus provid-
ing the best collective expertise of the experts  [28] . An-
other weakness might be the kind of sample of experts. 
There was no formal criterion for the recruitment of the 
experts although care was taken to have raters from many 
different disciplines.
 Even if data were available for all the harms of all the 
products on all the criteria, judgements would still be re-
quired to assess swing-weights. While the magnitude of 
harm of the most harmful product on each criterion can 
be informed by data, how much that worst-best differ-
ence matters requires an act of judgement. In this way, 
MCDA separates matters of fact from value judgements. 
As value judgements are at the heart of political debate, it 
might be instructive to engage in a public consultation 
exercise to allow different constituencies to  express their 
views about the weights. This could be a first step in ini-
tiating a structured deliberative discourse about nicotine-
containing products, as the politicians, the law and the 
public might weight the harm criteria differently  [29] . In 
addition, including the benefits of using nicotine prod-
ucts along with the harmful criteria might provide in-
sights into the nature of the benefit-harm  balance.
 The results of this study suggest that of all nicotine-
containing products, cigarettes (and small cigars in the 
USA) are very much the most harmful. Interventions to 
reduce this pre-eminence are likely to bring significant 
benefits not just to users but also to non-smokers and so-
ciety as a whole. Attempts to use other forms of nicotine 
such as ENDS and NRT to reduce cigarette smoking 
should be encouraged as the harms of these products are 
much lower.
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 Editors’ Note 
 The editors are aware that K.F. has 
connections with a company that is associ-
ated with one of the largest tobacco indus-
tries in the world (BAT: Nicoventures), 
but would like to notice that this stand-
alone company produces smoking cessa-
tion products, i.e. electronic cigarettes, 
that are now in discussion to be regarded 
as a new form of NRT. NRT is widely ac-
cepted as a treatment of patients with to-
bacco dependence. Therefore, the editors 
decided that the potential conflict of inter-
est of K.F. should not preclude acceptance 
and publication of this article. However, 
the scientific community has to discuss 
the demarcation between potential con-
flicts of interest related to companies pro-
ducing addictive drugs and companies 
producing therapeutics. 
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